A
Arialys Therapeutics
Developing precision medicines to block pathogenic autoantibodies for neuropsychiatric disorders
About Arialys Therapeutics
Arialys Therapeutics is a pioneering startup focused on addressing neurological and neuropsychiatric diseases through innovative treatments. The company operates in the biotech and pharmaceutical market, specifically targeting autoimmune neuropsychiatric disorders. These are conditions where the body's immune system mistakenly attacks the brain, leading to severe mental and neurological symptoms.
Arialys Therapeutics is dedicated to discovering and characterizing pathogenic autoantibodies in the central nervous system (CNS). Autoantibodies are immune proteins that mistakenly target and damage the body's own tissues. By identifying these harmful autoantibodies, Arialys aims to develop precision medicines that can block their activity, thus offering new treatment options for patients who currently have limited choices.
The company's business model revolves around research and development (R&D) of these novel therapeutics. Arialys invests heavily in scientific research to uncover new autoantibodies and understand their role in neuropsychiatric diseases. Once potential targets are identified, the company develops drugs designed to inhibit these autoantibodies. Arialys makes money by bringing these drugs to market, either through direct sales or by partnering with larger pharmaceutical companies for distribution and commercialization.
Arialys serves a diverse range of clients, including patients suffering from autoimmune neuropsychiatric diseases, healthcare providers looking for new treatment options, and pharmaceutical companies interested in innovative therapies. The startup's ultimate goal is to expand the treatment possibilities for neuropsychiatric disorders driven by autoimmune activity, thereby improving the quality of life for millions of affected individuals.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2022
- Headquarters
- San Diego, United States
- Employees
- 14
- Open positions
- None listed
- Dealroom signal
- 60.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Precision Medicine, Biotech and Pharma, Hard Tech, DT and LS, science-based
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEEDOther financing | Sep 2023 | $58M | $232M | Alexandria Venture Investments · Avalon BioVentures · Catalys Pacific · MPM BioImpact | ↗ |
Growth signals
Latest recorded traffic for Arialys Therapeutics is 2.3K monthly website visits, up 76.9% over the last three months. Arialys Therapeutics's team declined 26.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
Alexandria Venture Investments
Avalon BioVentures
Catalys Pacific
MPM BioImpact
Johnson & Johnson Innovation
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Arialys Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Arialys Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.